Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 4Sarcoma 2Plasma cell 2Other hematologic neoplasm 2Lymphoid 2Dermatologic 2Tumor-Agnostic 1Gynecologic 1CNS 1

Conditions

Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Carcinosarcoma 1

Interventions

Paclitaxel 74pembrolizumab 59Carboplatin 55Bevacizumab 54Specimen Handling 47Magnetic Resonance Spectroscopy 38Cisplatin 32olaparib 28Gemcitabine 25liposomal doxorubicin 24Biopsy 20Taxes 18Topotecan 17Nivolumab 17Doxorubicin 15Cyclophosphamide 15Immunoglobulin G 14Disulfides 14niraparib 12fludarabine 12lenvatinib 11Surveys and Questionnaires 11Letrozole 11atezolizumab 10Drug Therapy 10durvalumab 9Fulvestrant 9Docetaxel 9Brachytherapy 9mirvetuximab soravtansine 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
cobimetinib × Gynecologic × 90 days × Clear all
NCT05691504 2026-05-13

Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers

National Cancer Institute (NCI)

Phase 1 Active not recruiting
42 enrolled
GynecologicSarcoma

Carcinosarcoma, Fallopian Tube Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡